Media stories about Ligand Pharmaceuticals (NASDAQ:LGND) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ligand Pharmaceuticals earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.8053947994996 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern Sentiment’s analysis:
- BRIEF-Ligand Q3 adjusted earnings per share $0.69 (LGND) (uk.news.yahoo.com)
- Ligand Reports Third Quarter 2017 Financial Results (finance.yahoo.com)
- Ligand tops 3Q revenue forecasts (finance.yahoo.com)
- Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss (finance.yahoo.com)
- Xoma: A Lower Risk Way Of Investing In Biotech (finance.yahoo.com)
Ligand Pharmaceuticals (NASDAQ LGND) opened at $139.90 on Monday. Ligand Pharmaceuticals has a 12 month low of $95.08 and a 12 month high of $149.31. The company has a quick ratio of 0.95, a current ratio of 0.97 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $2,952.66, a PE ratio of 105.19, a price-to-earnings-growth ratio of 2.16 and a beta of 0.94.
Ligand Pharmaceuticals (NASDAQ:LGND) last issued its earnings results on Thursday, November 9th. The biotechnology company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.37 by $0.32. The business had revenue of $33.38 million during the quarter, compared to the consensus estimate of $31.04 million. Ligand Pharmaceuticals had a return on equity of 7.83% and a net margin of 12.76%. The firm’s revenue was up 54.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.62 EPS. equities analysts expect that Ligand Pharmaceuticals will post 2.35 earnings per share for the current year.
LGND has been the subject of several research analyst reports. Zacks Investment Research lowered Ligand Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 10th. HC Wainwright reaffirmed a “buy” rating and set a $157.00 target price on shares of Ligand Pharmaceuticals in a research report on Thursday, October 5th. Roth Capital reaffirmed a “buy” rating and set a $158.00 target price (up from $135.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday, October 11th. ValuEngine raised Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 10th. Finally, TheStreet upgraded Ligand Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Monday, August 7th. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $144.20.
WARNING: “Ligand Pharmaceuticals (LGND) Receiving Somewhat Favorable News Coverage, Study Shows” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://ledgergazette.com/2017/11/13/ligand-pharmaceuticals-lgnd-receives-daily-news-impact-score-of-0-16.html.
In related news, CEO John L. Higgins sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $130.00, for a total transaction of $650,000.00. Following the transaction, the chief executive officer now directly owns 144,171 shares of the company’s stock, valued at approximately $18,742,230. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jason Aryeh sold 2,000 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $127.99, for a total value of $255,980.00. Following the completion of the transaction, the director now directly owns 59,625 shares in the company, valued at $7,631,403.75. The disclosure for this sale can be found here. Company insiders own 14.70% of the company’s stock.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.
Receive News & Ratings for Ligand Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.